Clinical benefit with PEMAZYRE — 1 of 3

PEMAZYRE provides clinically meaningful responses

The efficacy of PEMAZYRE was investigated in the FIGHT–202 study in patients with previously treated CCA harbouring FGFR2 fusions or rearrangements (N=108)1

ORR1
(primary endpoint)

37

%

n=40

(95% CI, 27.94–46.86)

4 (3.7%)

patients had a confirmed CR1

36 (33.3%)

patients had a confirmed PR1

Median time to response1

2.7

Months

(range, 0.7–6.9 months)

82.4% (n=89) of patients achieved disease control (95% CI, 73.9–89.1)27

For further efficacy information, please refer to the PEMAZYRE Summary of Product Characteristics.1